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Abstract
Substantial advances have been made in identifying common genetic variants influencing cardiometabolic traits and
disease outcomes through genome wide association studies. Nevertheless, gaps in knowledge remain and new questions
have arisen regarding the population relevance, mechanisms, and applications for healthcare. Using a new high-resolution
custom single nucleotide polymorphism (SNP) array (Metabochip) incorporating dense coverage of genomic regions linked
to cardiometabolic disease, the University College-London School-Edinburgh-Bristol (UCLEB) consortium of highly-
phenotyped population-based prospective studies, aims to: (1) fine map functionally relevant SNPs; (2) precisely estimate
individual absolute and population attributable risks based on individual SNPs and their combination; (3) investigate
mechanisms leading to altered risk factor profiles and CVD events; and (4) use Mendelian randomisation to undertake
studies of the causal role in CVD of a range of cardiovascular biomarkers to inform public health policy and help develop
new preventative therapies.
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Introduction
After decades of inconsistent findings, firm genetic associations
are finally being reported for risk of coronary heart disease (CHD),
arterial aneurysmal disease, peripheral vascular disease and
diabetes [1–5], and for major atherosclerotic risk factors (LDL-
cholesterol [6], blood pressure (BP) [7], and smoking behaviour
[8]). Moreover, variants have been identified for their associations
with many other cardiovascular disease (CVD)-associated bio-
markers of less certain causal relevance, including HDL-choles-
terol and triglycerides [6], apolipoproteins [9], lipoprotein (a) [10],
inflammation and coagulation factors [11], uric acid, and glucose
[12]. This progress in cardiovascular genetics has been made
possible by sequencing the human genome [13,14], characterising
the frequency and correlation between genetic variation (1000
Genomes Project and the human HapMap) and exploiting
technical advances in array-based genotyping. The assembly of
large case-control collections for genome wide-association studies
(GWAS) using microarrays that genotype up to 1 million single
nucleotide polymorphisms (SNPs), the use of stringent significance
thresholds for association, and rigorous validation by replication in
independent studies [15,16], have all contributed to these major
advances in genetic epidemiology.
Conservative significance thresholds required to reduce false-
positive associations can lead to trait-associated variants of modest
effect being overlooked in insufficiently large samples. Identifying
these loci is still valuable because of the insight provided on disease
aetiology and possible drug targets. To this end, multiple GWAS
are being pooled by consortia usually focusing on a single trait or
disease end-point, e.g. diabetes (DIAGRAM [5]), CHD (CAR-
DIoGRAM [17]), stroke (the Stroke Genetics Consortium [18]),
BP (the International Consortium of BP-GWAS [19]), lipids (the
Global Lipids Genetic Consortium [20]), plasma glucose and
related traits (MAGIC [21]), smoking behaviour (Ox-GSK [8]),
and electrocardiographic QT-interval (QT-IGC). The contribut-
ing studies represent a mix of study designs, and include
geographically diverse populations with differing risk factor
exposures, CVD event rates, and age ranges. These studies
usually provide cross-sectional disease outcome and phenotype
data.
Genotyping arrays for GWAS provide broad coverage of the
genome through SNPs that capture information on un-typed SNPs
due to linkage disequilibrium (LD). Because of LD between
variants, multiple associated SNPs are observed at each locus,
mostly in non-coding DNA regions [22], which may span several
genes, or may be remote from known genes. Replication usually
centres on just one or two strongly associating SNPs. Consequent-
ly, determining the identity and number of causal variants is often
difficult, owing to the potentially large number of unexamined
variants. Fine mapping, using denser SNP association data from
re-sequencing or custom gene/locus-centric SNP arrays, can help
resolve causal genes and SNPs. Therefore, despite the success of
GWAS, unanswered questions remain. These include: (1) the
precise location of the causal SNP(s) and the gene(s) they influence;
(2) the absolute (as opposed to the relative) effects of loci, and how
these change with age or differing non-genetic exposures; (3) the
combined influence of multiple disease- or trait-associated SNPs;
(4) the full constellation of risk factors and biomarkers influenced
by each SNP (pleiotropy); and (5) the precise mechanism by which
many CVD-associated SNPs lead to disease.
These residual uncertainties can be addressed by higher
resolution SNP typing at associated loci using gene-centric arrays,
such as the Metabochip [23], in highly phenotyped, prospective
cohort studies with serial risk factor/biomarker measures and
information on incident disease. The Metabochip provides
improved imputation accuracy, as well as greater power for
detecting associations with common variants in fine mapping
regions (122,241 SNPs are on the array to fine-map 257 loci which
showed genome-wide significant evidence for association with one
or more of the 23 cardio-metabolic traits), compared to GWAS
arrays due to the increased SNP density of the Metabochip in
genic regions [23], therefore offering an advantage for genetic
association analyses. In addition, SNPs were selected from the
databases developed by the International HapMap Project
(http://www.hapmap.org) and the 1000 Genomes Project
(http://www.1000genomes.org), allowing inclusion of SNPs across
a wide range of the allele frequency spectrum, including those with
a minor allele frequency of less than 0.1%.
The UCL-LSHTM-Edinburgh-Bristol (UCLEB) Consortium
has been established to allow interrogation of genetic associations
using the Metabochip. The consortium consists of 12 well-
established prospective observational studies comprising over
30,000 participants: Northwick Park Heart Study II (NPHS II),
Whitehall-II Study (WHII), British Regional Heart Study
(BRHS), English Longitudinal Study of Ageing (ELSA), MRC
National Survey of Health and Development (MRC NSHD),
1958 Birth Cohort (1958BC), Edinburgh Artery Study (EAS),
Edinburgh Type 2 Diabetes Study (ET2DS), Edinburgh Heart
Disease Prevention Study (EHDPS), Aspirin for Asymptomatic
Atherosclerosis Trial (AAAT), Caerphilly Prospective Study
(CaPS) and the British Women’s Heart and Health Study
(BWHHS). The unique properties of the consortium provide an
opportunity to investigate genetic determinants of risk factors for
CVD through Metabochip-wide association analyses (MWAs), as
well as associations with measures of subclinical disease such as
carotid intima media thickness (cIMT), and with clinical events.
Integration of genotype, biomarker and disease outcome data can
also provide insight into disease mechanisms and potential
therapeutic targets.
Design of the UCLEB Consortium
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Methods and Design
Cohorts
All 12 studies in the UCLEB consortium are UK-based with
wide geographic representation. Participants are almost exclusive-
ly of European ancestry. Principal components analysis (PCA) has
been used to investigate the presence of population structure and
exclude outliers. The age at recruitment ranges from birth (MRC
NSHD and 1958BC) to .90 years (ELSA), with most cohorts
recruiting subjects in mid-life. Despite the range of ages at the time
of recruitment, the current age of participants spans the 5th to 9th
decades of life, a time at which the majority of common, non-
communicable diseases manifest, rendering the consortium a
valuable continuing source for cases of incident diseases. All
studies have longitudinal follow up (range 5–62 years) and details
of incident disease (see Table 1). Each of the studies has a
prospective cohort design, the MRC NSHD and 1958BC also
being birth cohorts. The AAAT study was designed as a RCT but
the prospective follow-up allows inclusion as a cohort study. All
have a DNA repository with most studies already having published
genetic analyses. There are various existing collaborative links
between the studies; MRC NSHD, 1958BC, ELSA, CaPS and
WHII in the HALCyon network; MRC NSHD, 1958BC, BRHS,
ELSA, WHII, NPHS II and EAS as the UCL Genetics
Consortium, and BRHS and BWHHS as sister studies with the
same sampling frame and clinic procedures.
Each of the studies has a defined sampling frame, inclusion
criteria, and procedures for the collection and recording of
demographic details, biological samples, and clinical measures.
Each of the 12 cohorts has a wide range of clinical and biological
measures with overlap across studies, facilitating pooled analyses
with substantial power. Many have also used common or
comparable measurement methods with many of the blood
markers having been measured in the same laboratory. All studies
follow participants for incident disease and mortality, and have an
ongoing programme of clinical assessments/biological sampling.
The UCLEB consortium currently includes Metabochip infor-
mation [23] augmented by imputation using the 1000 Genomes
(http://www.1000genomes.org) dataset (1 million typed and
imputed SNPs) from 8 studies consisting of around 21,000
samples, more than 100 phenotypes. These include a maximum
of 70 blood and other biomarkers (of which 19 are available in
more than 15000 participants); carotid ultrasound measures of
atherosclerosis from 7200 individuals across 5 studies (MRC
NSHD, WHII, BRHS, EAS and ET2DS); around 2000 cases of
prevalent and incident type 2 diabetes; and almost 6000
cardiovascular events (see Tables 2 and 3).
UCL-based studies
Northwick Park Heart Study II (NPHS II) [24]. From
April 1989 to April 1994, 3012 healthy Caucasian men, aged 51–
60 years, registered with 9 general medical practices across the
UK were recruited for prospective surveillance. All eligible
subjects were free of a history of unstable angina, MI or evidence
of silent infarction, coronary surgery, aspirin or anticoagulant
therapy, cardiovascular disease, malignancy (except skin cancer
other than melanoma), or any condition precluding informed
consent. Non-fasting plasma samples were taken at baseline and
annually until year 6. A standard ECG was recorded and coded
according to Minnesota criteria at baseline and at 6 years.
Baseline plus 5 annual repeat measures are available in the entire
cohort on BMI, lipids, DBP, SBP, fibrinogen and FVII. Single
measures of homocysteine, Lp(a), and CRP are available. Repeat
phenotypes were measured at the same centres and are complete
for all those mentioned. Smoking status is known. Endpoints for
CHD were fatal and non-fatal MI based on WHO criteria, silent
MI or coronary revascularization procedures and sudden unex-
plained death. Information on fatal cancers and diabetes has also
been recorded. DNA was extracted from blood samples collected
in 2000.
British Regional Heart Study (BRHS) [25]. From 1978 to
1980, 7735 men aged 40–59 were recruited from general practices
across the UK. A wide range of phenotypic measures is available
for established risk markers such as lipids, blood pressure and
inflammatory and haemostatic markers. Most of these measures
were taken both at recruitment and re-examination, which
occurred in 1998–2000 when men were aged 60–79. At this re-
examination 4252 participants attended and DNA was extracted
Table 2. Measures available in the UCLEB consortium.
Number of aggregate measures Phenotypes
.35,000 SBP, DBP, Smoking, Total Cholesterol, Fibrinogen, BMI, Height, Weight, Alcohol consumption
.30,000 LDL, HDL, Triglycerides, Social class, Physical activity
.25,000 Waist-hip ratio, HbA1c, CRP, Respiratory function (FEV1, FVC and PEFR), von Willebrand factor
.20,000 Glucose, Stress, Verbal memory, Factor VII
.15,000 D-Dimer, Educational achievement, Viscosity, ECG, Tissue plasminogen activator, IL-6, Cortisol, Short term memory,
Insulin, MRC respiratory questionnaire, White cell count, Creatinine, eGFR
.10,000 Muscle function (Walking speed, Standing balance, Grip strength and Chair rises), Lp(a), Liver function (ALT, AST and
GGT), ApoAI, ApoB, Mental flexibility (TMT), Homocysteine, Cognitive function (Mill Hill VS, Letter search/cancel, WMS
logical/verbal memory, MMSE, Non-verbal reasoning, Processing speed (DST) and AH4)
.5,000 Digitised ECG (PR interval, QRS duration, QT interval and indices of left ventricular hypertrophy), Pulse wave velocity,
Haematocrit, Prothrombin, Ferritin, IGF-1, cIMT, Cotinine, Telomere length, I-CAM, skin folds, V-CAM, ApoE, Platelets
.2,500 Arterial distensibility, Heart rate variability, ABPI, TNF-a, Bilirubin, Leptin, Dehydroepiandrosterone sulfate, Fibrin
peptide A, Proteinuria, Factor VIII, Factor IX, Activated partial thromboplastin time, Activated protein C added to the
Activated partial thromboplastin time, Activated protein C and Activated partial thromboplastin time, Alkaline
phosphatase, Serum urea, Serum potassium, Serum sodium, Serum urate, Serum magnesium, Serum calcium, Serum
phosphate, Total serum protein, Red blood cell count, Haemoglobin, Mean cell volume, Mean platelet volume,
Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basinophils, Vitamin C, Vitamin E, Beta-carotene, Adiponectin, IL-
18, MMP-9, sCD40L, Natriuretic peptide, E-selectin, Flow-mediated dilation, Pulse-wave analysis, ApoAII
doi:10.1371/journal.pone.0071345.t002
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for 3945. A case-control sample was selected using 1095 cases
with prevalent data at re-examination or incident cases of CHD
or stroke over the next 8 years and 1358 controls. The controls
were frequency matched based on being in the same town and
within the same fixed 5-year age band as the cases. Data on
important behavioural variables such as cigarette and alcohol
consumption, as well as physical activity, have been regularly
collected through follow up. Well validated outcome variables
such as major coronary heart disease, stroke, diabetes, and
revascularisation, as well as cause-specific mortality, continue to
be collected from medical records almost 30 years after
recruitment.
(http://www.ucl.ac.uk/pcph/research-groups-themes/brhs-pub).
Whitehall II Study (WHII) [26]. Whitehall II recruitment
of 10,308 participants (70% men) between 1985 and 1988
involved 20 London based Civil service departments. Genetic
samples were collected in 2004 from over 6,000 participants.
The study is highly phenotyped for cardiovascular and other
ageing related health outcomes, with 9 phases of follow up (5
with clinical assessment and biological sampling), over 20 years
of follow up. A wide variety of health behaviour and
environmental data are also collected and the participants are
consented for linkage to recorded clinical data such as Hospital
Episode Statistics (HES), the Office of National Statistics
mortality data and the national registry of acute coronary
syndromes in England and Wales (Myocardial Ischaemia
National Audit Project).
(http://www.ucl.ac.uk/whitehallII/).
English Longitudinal Study of Ageing (ELSA) [27]. This
is a national cohort of participants (48% men) aged over
50 years recruited from the Health Surveys for England in 1998,
1999 and 2001. Genetic data were collected at Wave 2 of the
study (2004/5). A wide range of phenotypic measures relevant to
ageing are available. These measures were made at Wave 0 of
the study (1998, 1999 and 2001) and at follow up (2004/5). Data
on health behaviours and a wide range of health outcomes are
available. Nearly all participants (97%) are also consented to
linkage to routine data such as HES, which allows for the
assessment of health outcomes and cause specific mortality. A
case-control sample was selected using 412 cases and 1573
controls. Controls and cases were matched by sex and 5-year
age bands at Wave 2.
(http://www.ifs.org.uk/elsa/).
Medical Research Council National Survey of Health
and Development (MRC NSHD) [28]. This is an on-going
prospective birth cohort study consisting of all births in England,
Scotland and Wales in one week in March 1946. The sample
includes single, legitimate births whose fathers were in non-
manual or agricultural occupations and a randomly selected one
in four of all others, whose fathers were in manual labour. The
original cohort, now 66 years of age, comprised 2,547 women
and 2,815 men who have been followed-up over 20 times since
their birth. The data collected to date include repeat cognitive
function, physical, lifestyle and anthropomorphic measures, as
well as blood analytes and other measures. The cohort recently
completed a particularly intensive phase of clinical assessment
and biological sampling with blood and urine sampling and
analysis, and cardiac and vascular imaging [29]. DNA was
extracted from blood samples collected in 1999. Follow-up for
disease outcomes is by self-reports of doctor diagnosed events
that have been validated against General Practice (GP) records.
(http://www.nshd.mrc.ac.uk/).
1958 Birth cohort (1958BC) [30]. 1958BC is a prospec-
tive birth cohort study consisting of all births in England,
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Scotland and Wales in one week in March 1958. Participants to
the cohort have been followed-up regularly since birth with
prospective information collected on a wide range of indicators
related to health, health behaviour, lifestyle, growth and develop-
ment. There have been 9 contacts with the participants since their
birth (ages 7, 11, 16, 23, 33, 41, 45, 47, and 50 years). The
biomedical survey at age 45 years included collection of blood
samples and DNA from about 8000 participants. Immortalised cell
lines providing an unlimited resource for future genetic studies
have been created for 7500 participants. Follow-up for disease
outcomes is by self-reports of doctor diagnosed events and record
linkage for fatal events.
Bristol/London School-based studies
Caerphilly prospective study (CaPS) [31]. This study is
based on men aged between 45 to 59 years who resided in the
small South Wales town of Caerphilly between the examination
dates of 1979 &1983. Of the 2818 eligible, 2512, (89%) were
recruited. The men were studied at baseline (Phase 1) and each
subsequent 5 year period (Phase 2–5) and have therefore been
followed up for around 20 years. An additional 447 patients were
recruited at phase 2. The cohort has a wide range of
cardiovascular phenotypes and at phase 3, cognitive function
was also assessed, which has been supplemented with clinical
dementia and cognitive impairment at phase 5. DNA was
extracted from blood samples collected in 1992–1994. Follow-up
for disease outcomes is by self-report from participants, who are
also linked to hospital episode discharge summaries for validation
checks to comply with WHO criteria, as well as death certificates
for fatal events.
(http://www.bris.ac.uk/social-community-medicine/projects/
caerphilly/about).
British Women’s Heart and Health Study (BWHHS)
[32]. Established in 1999 as a study of women to parallel the
BRHS, it used the same sampling frame and very similar clinic
protocols to the 20 year follow-up of BRHS. From 1999–2001,
4286 women aged 60–79 were randomly selected from 23 general
practices across the UK. A wide range of phenotypic measure-
ments were obtained at baseline including anthropometry, blood
pressure, ECG, lung function tests and fasting blood samples.
Glucose, insulin, lipids, clotting and inflammatory markers have
been assayed and stored serum is available. DNA was extracted
from blood samples collected at baseline in 1999–2001. Data on
sociodemographic and lifestyle variables such as cigarette smoking,
alcohol consumption, diet, physical activity, reproductive health,
education, occupation, quality of life, and activities of daily living
have been collected repeatedly (baseline, years 3, 7, and 12).
Follow-up for disease outcomes is by biennial medical record
review (with validation checks) and cancer registrations and death
certificates obtained from the National Health Service (NHS)
Central Registration. Detailed follow-up is collected on coronary
heart disease, stroke, type 2 diabetes, pulmonary embolism, deep
vein thrombosis and cancer events. The UCLEB case-control
sample was selected using 523 cases with prevalent disease at
recruitment or incident cases of CHD or stroke up to 2010. 1501
controls were frequency matched based on being in the same town
and within the same fixed 5-year age band as the cases.
(http://www.lshtm.ac.uk/eph/ncde/research/bwhhs/index.html).
Edinburgh-based studies
Edinburgh Artery Study (EAS) [33]. At baseline (August
1987-September 1988), an age-stratified random sample of men
and women, aged 55–74 years, was selected from the age-sex
registers of ten general practices with catchment populations
spread geographically and socioeconomically throughout the city
of Edinburgh. Subjects were excluded if they were unfit to
participate (e.g. due to severe mental illness or terminal disease).
These exclusions were replaced by other randomly sampled
subjects. The study population is almost exclusively European.
DNA was extracted at 5 years follow-up. Physical examinations
were performed by specially trained research nurses using
standardised operating procedures. The quality of clinical
measurements were checked before and during the study by
repeat measurements taken intermittently by the study co-
ordinator. Individual observer measurements were assessed for
drift. Blood assays were performed in accredited laboratories using
international standards. Subjects have been followed up for
20 years for cardiovascular events, using repeat self-reporting
questionnaires, record linkage for hospitalisations and deaths, and
validation of events against pre-specified criteria through searching
of hospital and GP notes. Comprehensive clinical examination was
repeated at 5 and 12 years after commencement of the study,
resulting in repeat measurements of several key variables.
Edinburgh Heart Disease Prevention Study (EHDPS)
[34]. At baseline (1985–1987), all men aged 30–59 years and
registered with one of two general practices in the city of
Edinburgh, were invited to participate in this study. The response
rate was 69% and follow-up of non-responders showed that there
was no substantial bias. DNA was extracted at baseline. Physical
examinations were performed by a specially trained research nurse
using standardised operating procedures. Blood assays were
performed in accredited laboratories using international standards.
Subjects have been followed up after 20 years for cardiovascular
events, using repeat self-reporting questionnaires and record
linkage for hospitalisations and deaths.
Edinburgh Type 2 Diabetes Study (ET2DS) [35]. At
baseline (August 2006 to August 2007), an age-stratified random
sample of men and women with type 2 diabetes, aged 60–74 years,
was selected from the Lothian Diabetes Register (LDR), a
comprehensive database of subjects with known type 2 diabetes
living in Lothian. Subjects were excluded if they did not meet
WHO criteria for type 2 diabetes, or if they were physically unable
to complete the clinical and cognitive examination. The study
population is almost exclusively European. DNA was extracted at
baseline. Physical examinations were performed by specially
trained research nurses using standardised operating procedures.
The quality of measurements was checked using observation of
research staff by study investigators and inter-observer variability
assessments were made for key variables. Blood assays were
performed in accredited laboratories using international standards.
Retrospective data on cardiovascular disease and selected physical
and biochemical variables were retrieved using record linkage for
hospitalisations and deaths since 1985 and using data from the
LDR. Subjects returned for further clinical examination after one
year and were examined again after they had participated for
4 years.
Asymptomatic Atherosclerosis Aspirin Trial (AAAT)
[36]. At baseline (1998 to 2000), all men and women aged
50–75 and registered with participating general practices spread
throughout Edinburgh, Glasgow and Lanarkshire (83% of all
practices within study area), were invited to participate in this
study. Subjects were excluded if they had a history of MI, stroke,
angina or peripheral arterial disease (PAD) and included if they
had an ankle brachial index of 0.9 or less. They were therefore a
healthy, but moderately increased risk population, in terms of
cardiovascular disease. Subjects were further excluded if they were
currently using aspirin or other antiplatelet or had a contraindi-
cation to aspirin therapy. Subjects were followed up for 8 years for
Design of the UCLEB Consortium
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cardiovascular events, using annual contacts with subjects, record
linkage for hospitalisations and rigorous validation of events
against pre-defined criteria using hospital and GP notes. Physical
examination was performed at baseline and after 5 years by
specially trained research nurses using standard operating
procedures, and blood assays were performed in accredited
laboratories using international standards. DNA was extracted
3 months after recruitment.
Work flow and organisation
The workflow developed to co-ordinate genotyping, merge and
collate with harmonised phenotype and disease end-point data is
summarised in Figure S1.
Organisation and governance
Informed consent was obtained for all subjects included in
UCLEB research. Written approval from individual Research
Ethics Committees to use anonymised individual level data has
been obtained by each participating study. All data obtained and
generated within the UCLEB consortium are fully anonymised,
contain no personal identifiers and adhere to the contributing
studies restrictions on deductive disclosure. Senior investigators
from each participating study were invited to join the UCLEB
steering group to discuss key projects to be carried forward and to
assess the potential for external collaborations. An analysis group
meets weekly focusing on methods development and analyses.
There are regular weekly teleconferences organised from the
coordinating centre at UCL during which the whole consortium is
updated on various aspects of genotype and phenotype data
management, and on-going and proposed analyses. An access-
restricted Google-hosted website has been set up to facilitate
sharing of minutes, analysis plans, project proposals and other
useful resources. The cohorts included in the UCLEB consortium
have individual policies and mechanisms for data sharing and all
have an excellent track record in this regard. Most of the studies
have contributed to the highly cited Emerging Risk Factors
Collaboration reports on CV risk factors and biomarkers, and to
GWAS consortia and other large-scale genetic discovery efforts.
Opportunities for data sharing are maximised because requests to
individual studies are also possible, e.g. for projects that focus on
certain study designs or where outcomes are available only in a
subset. The proposals to access UCLEB data are evaluated by
members of the steering committee using a standardised data
request form. Aggregate SNP data for specifically requested traits
are shared with external collaborators according to the external
project analysis plan.
Genotyping
Around 21,000 individuals across the cohorts have been typed
using Metabochip (see Table 4), a genotyping platform consisting
of ,200,000 SNPs, which cover the loci identified by GWAS in
cardiometabolic diseases, and rare variants from the 1000
Genomes Project [23]. This will be supplemented by SNP data
from a whole genome array in the 1958 Birth Cohort, the 50 k
HumanCVD Beadchip [37] in WHII and BWHHS, and prior
candidate and GWAS replication work in all studies. The NPHS-
II, EHDPS and AAAT studies are available for new bespoke
genotyping e.g. to validate associations from UCLEB samples
genotyped by Metabochip. This will yield a powerful aggregate
dataset rich in genetic and phenotypic detail.
Duplicate samples have been genotyped to compute the error
rate. Initial quality control analysis on genotyped data identified
any problem samples that have been subsequently excluded in
further analysis. These included: checks for discordance between
reported and genetically-determined ethnicity, replicate concor-
dance, sample mix-up (unknown duplicates and comparison to
previously genotyped data where available), gender ambiguity and
cryptic relatedness (see Figure S1).
Imputation using data from 1000 Genomes
Although coverage of the genome is less comprehensive using
the Metabochip than a whole genome array, imputation against
the 1000 genomes European ancestry reference sample extends
coverage from 200,000 to approximately 1 million SNPs, when
the R2 is $0.8 (see Table 4), with dense coverage of loci of
interest for cardiometabolic disease, including approximately 70%
of the druggable genome. Imputation using Metabochip data
served to fine-map in and around regions covered by the array.
However, the gene-centric nature of Metabochip means that there
are extensive intergenic regions of the genome that have no SNP
coverage, and therefore, imputation provided little additional
information in these regions. Our imputation process was based on
the strategy summarised at: http://genome.sph.umich.edu/wiki/
Minimac:_1000_Genomes_Imputation_Cookbook, and proceed-
ed in three distinct stages: chunking, phasing and imputing.
Chunking
To speed up the overall imputation process, the genome was
broken into overlapping chunks specified by reference to the
physical map. Each chunk consisted of 1000 consecutive SNPs and
consecutive chunks overlapped by 250 SNPs. The final chunk in
each chromosome consisted of any remaining SNPs (less than
1000) plus a 250 SNP overlap with the penultimate chunk.
Phasing
Each chunk was phased using the program MACH1 (down-
loaded from: http://www.sph.umich.edu/csg/abecasis/MACH/
download/), which implements a Markov Chain Monte Carlo
(MCMC) Haplotyping algorithm [38,39]. The phasing process
can be set to consider all possible haplotypic states for the
genotypes but this is too computationally intensive to be practical.
We therefore phased each chunk considering 500 states and the
number of rounds of MCMC was set to 30.
Imputation
Phased haplotypes were used as a basis for imputation of
untyped SNPs using the method described by Li et al. 2010 [39],
which used an external set of reference haplotypes (1000 genomes,
February 2012 release, CEU haplotype set) to infer the most likely
allele call for untyped loci. The method was implemented using
the software Minimac (downloaded from: http://www.sph.umich.
edu/csg/cfuchsb/minimac-beta-2013.7.17.tgz. Following imputa-
tion, chunks were reassembled into full chromosomes. The
genotypes for SNPs that lay in overlapped regions were taken
from the chunk in which the R2 statistic for imputation quality was
greatest.
The UCLEB data was collated in a dosage format, which is
readily utilised by the analytical package PLINK [40], as well as in
probability format that can be used by the R Package snpStats
(downloaded from: http://www.bioconductor.org/packages/2.
10/bioc/html/snpStats.html), which offers a useful range of
analytical functions coupled with the flexibility of the R
programming environment for data manipulation and further
analysis.
Design of the UCLEB Consortium
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Phenotype and disease endpoints
Phenotypic data available for sharing from each study were
harmonized to agreed units and categories determined by
individual study and phenotype data managers. Data were then
collated at the UCLEB coordinating centre (Table 3). Disease
definitions were as follows: CHD is all non-fatal myocardial
infarction (MI) or any revascularisation procedure (coronary artery
bypass surgery or angioplasty) and fatal CHD. Stroke is all non-
fatal stroke (ischaemic & haemorrhagic combined) excluding TIA
and fatal stroke. Fatal events are defined or matched according to
a pre-defined list of ICD codes. Type II diabetes is based on either
self-reported, medical history review, taking glucose lowering
medication, or a fasting glucose .7 mmol/L. Medication data
were also collated, including those on lipid lowering drugs (statins
or other medication), blood pressure lowering drugs, and glucose
drugs (Table 3).
Analyses
Analysis plans have been written that can be adapted by each
working group for specific analyses, and Stata, PLINK and R
syntax are available for these analyses. In order to address the core
aims of UCLEB, five broad analytical approaches will be applied.
(a) Metabochip-wide genetic discovery analysis to be run
individually on each study, from which study-specific
estimates will be pooled by fixed effects meta-analysis
weighting by inverse variance using the METAL program,
as well as by random effects meta-analysis, to generate
summary estimates for each trait. Medication use for the
main drug classes affecting cardiometabolic traits (cholester-
ol, blood pressure and glucose) has been carefully recorded.
Previously validated methods [41,42] for adjusting genetic
associations for medication use will be applied. Heterogene-
ity will be estimated by Cochran’s Q statistic and the I2 value
(and 95% confidence interval; CI). SNPs most likely to mark
or represent causal sites will be identified using variable
selection methods, as well as conditional analyses to identify
independent SNPs at each locus applying locus-specific
Bonferroni correction.
(b) Analysis of multiple phenotypes (phenome scans) for
improving power and investigating pleiotropy. Considering
the extra information provided by the covariance between
the traits allows the joint analysis of multiple phenotypes, in
order to increase power. One such implementation is
MultiPhen [43], in which the genotype of each SNP is
regressed on a group of phenotypes. Pleiotropy will be
explored in two ways; (i) using Bayesian statistical method-
ology, where the association between multiple phenotypes
and multiple SNPs will be analysed simultaneously using the
GUESS software [44]; and (ii) through phenome scans based
on associations reported in prior studies, where the
association of a selection of known disease associated genetic
loci is tested for the large number of available phenotypes in
the UCLEB data to establish common pathways and
functional links.
(c) Application of genetic associations in risk prediction models.
The absolute, relative and attributable genetic risk of CVD
events (overall, and separately for fatal/non-fatal CHD and
stroke) will be estimated and compared with the associations
of non-genetic risk factors using SNPs identified by prior
GWAS that are included in Metabochip. Analyses will use
Cox proportional hazards models and derived hazard ratios
(HRs). Risks will be estimated within study and pooled by
random effects meta-analysis with exploration of heteroge-
neity and effect modification by strata of age, CVD risk
factors, and by geographic region. We will generate standard
prediction metrics (e.g. C-statistics, net-reclassification,
integrated discrimination index) that will compare the
benefit of genotypes for CVD prediction with established
non-genetic risk scores. The large number of incident CV
events in the UCLEB consortium (.5000) will allow precise
risk estimates to be obtained and minimise potential false-
positive findings.
(d) Mendelian randomisation (MR) analyses. MR studies
typically quantify and compare three associations: (i)
biomarker-disease in prospective cohort studies; (ii) geno-
type-biomarker in cross-sectional or prospective cohort
studies; and (iii) genotype-disease in prevalent case-control
studies or studies of incident cases and controls nested within
a cohort study. Triangulation of the risk estimates provides
evidence on causation, with the magnitude of the causal
association being estimated by instrumental variables
regression. Despite emerging successes of MR, two limita-
tions remain. First, many biomarker-associated SNPs are of
weak effect, compromising power and necessitating large
sample sizes. Second, although SNPs identified for an index
association with a single CVD risk factor/biomarker are not
generally associated with exogenous exposures influencing
CVD risk (e.g. diet, physical activity, socioeconomic status),
they are frequently associated with a diverse range of
endogenous biomarkers. This can compromise interpreta-
tion of an MR analysis based on a single locus. The issue of
power is addressed in UCLEB both through use of gene
scores and through external collaboration with other studies
and consortia to ensure case numbers are not limiting. The
use of genetic instruments comprising SNPs from different
genetic loci, each independently associated with the
biomarker of interest, increases power, since each SNP
contributes incrementally to the marker variance, and also
helps reduce non-specificity, because the relative genetic
effect on traits other than biomarker of interest tends to
attenuate.
(e) Genetic effects on risk factor/biomarker trajectories. Anal-
ysis of risk factor trajectories will involve generation of
standard deviation scores for each trait, cross-sectional
descriptive analyses at different ages, and the development
of hierarchical mixed models which account for correlation
between repeated measures, as well as age-by-genotype
interaction tests. We will use multiple imputation for the
management of missing data.
Figure S2 gives additional information on the analyses that
have been prioritised by UCLEB.
Power calculations
Power and sample size calculations were conducted to evaluate
the ability of the UCLEB datasets to discover novel loci and to test
the effect of loci validated for an index trait on other traits and
outcomes. Conservative alpha values of 161027 (GWAS level)
were adopted for the former and 1024 for the latter. All sample
size estimates correspond to the total number of individuals and
assume a 10-year CVD event rate of 16%, based on average age,
follow-up period and gender of participants in UCLEB cohorts.
Quantitative traits. For quantitative traits, a good approx-
imation for the sample size is given by N= (za+zb)2/q2 where za
and zb are values of the standard normal distribution for specified
alpha and beta error and q2 is the amount of variance explained,
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which is determined by effect size and minor allele frequency in
the case of single SNPs. In addition to alpha and sample size,
power depends on the variance explained by a SNP, which is in
turn related to minor allele frequency (MAF, pAu) and effect size
(d) and is given by q2= 2pAu(1-pAu)d
2. Tables S1a and S1b
present the resulting power estimates in order to be able to discover
SNPs that explain as little as 0.5% of the variance with 80% power.
The tables provide power for sample sizes in the range 2,500 and
20,000 to detect variance in a quantitative trait of 0.5–5% at a p-
value of 1027 (Table S1a), and a p-value of 1024 (Table S1b).
Events. For disease events, power depends additionally on
incidence rate. A differentiation is made between common alleles
(see Tables S2a and S2b) and rare alleles (see Tables S2c and
S2d). Higher MAFs are often accompanied by smaller effect sizes
while rare alleles have a higher likelihood of larger effects. As
illustrated by Tables S2a–d, the combination of very small MAF
and very small effect leads to a substantial inflation of the effect of
sample size on power. With an overall sample of 30,000 subjects,
and a 16% 10-year event rate, power estimates mostly exceed 80%
for a range of plausible effect sizes. For example, with a total
sample of 27,323 individuals among whom the 10-year event rate
is 16%, power to detect a common SNP with MAF of 15% and
odds ratio of 1.2 is 80%. With regard to rare alleles that have a
frequency of only 1%, achieving a power of 80% for an odds ratio
of 2, requires 18,456 subjects.
Discussion
UCLEB is a large-scale epidemiological resource bringing
together diverse expertise across studies, scientific advisors,
phenotype experts, statistical experts and analysts. UCLEB has
an established research governance structure, data sharing
arrangements, steering, operations and analysis groups, a central-
ised, secure, access-managed genetic and phenotypic data
repository, and agreed analysis protocols. The strength of
cohort-based analyses is that genetic loci can be identified for
every quantitative trait recorded in sufficiently large numbers.
UCLEB has more than 100 traits indexing 16 organs and
biological systems. Moreover, as well as the established 1-trait: 1-
Metabochip-wide analysis model, there is an opportunity to
integrate Metabochip information, for example, to identify
quantitative traits with overlapping genetic regulation and genetic
loci with effects on multiple pathways.
Heritability estimates provide an indication of the overall
genetic contribution, but not the number of genes influencing a
trait or the size of effect. Despite similar heritability, genes for
some traits such as blood inflammation markers [45,46] have been
identified by moderately-sized GWAS, while others such as BMI
[47] and height [48] have required much larger data sets to
identify genes of smaller effect with statistical confidence. In
general, traits more proximal in the pathway from genome
variation to disease (e.g. blood proteins and metabolites) are likely
to be identified with smaller sample sizes than distal (higher order)
phenotypes such as ECG parameters and BP. However, expansion
of the population resources in both domains would be beneficial
even for traits where some genetic loci have already been identified
(e.g. LDL-cholesterol), because of the large residual unexplained
phenotypic variance. For the majority of traits in this consortium,
the genetic determinants have yet to be fully characterised.
By exploiting measures of continuous phenotypes where
available, case-control GWAS have not only provided insight on
disease-associated loci but have also started to uncover genetic
effects on quantitative traits. However, highly-phenotyped,
population-based prospective studies are particularly suited for
genetic analysis of quantitative traits because of: (1) the range of
measures; (2) longitudinal follow-up that also allows exploration of
genetic effects on trajectories, and at critical periods; (3) the
addition of new phenotypic detail with new waves of resurvey and
data collection, which enrich the resource, so that the value of the
investment in genotyping extends beyond any single trait or
outcome; (4) assessment of context dependent genetic effects
because of exhaustive information on diet, records (and sometimes
objective measures) of smoking and physical activity, as well as
education, employment, medication and many other environmen-
tal factors [49,50]; and (5) repeated measures not only of many of
the outcomes of interest but also some of the important
environmental modifiers (e.g. smoking, alcohol consumption,
physical activity and social indices), which will help improve
precision by allowing control for regression dilution bias, and will
facilitate analysis of gene-environment interaction [51]. Together
with the use of the Metabochip SNP array that more densely
captures genome variation, including rare and copy number
variants, this should allow more comprehensive evaluation of
genetic effects on disease-relevant traits.
A number of large consortia have already been assembled to
discover and subsequently fine map genetic associations of
cardiometabolic traits and disease end points [52–54] using
Metabochip. UCLEB studies have already contributed to some of
these efforts, but these are typically based on sharing of summary
level data on a narrow range of phenotypes or disease end-points.
The added value of the UCLEB consortium comes from the ability
to undertake discovery of the genetic loci for less commonly
available phenotypes not currently the subject of consortium based
efforts, extend the associations of known cardiometabolic loci to a
wider range of phenotypes (phenome scans), to investigate the
effects of known genetic variants on biomarker trajectories and
variability (where repeat measures are available), to evaluate the
predictive utility of known disease associated genetic variants for
incident CVD events, and to generate and optimise genetic tools for
Mendelian randomisation analyses based on effect size and
specificity for the trait of interest. In this respect, the UCLEB is
most similar in design, organisation, exposure measures and aims to
two other assemblies of population based studies engaged in
collaborative genomic research. These are the National Heart
Lung and Blood Institute Candidate Gene Association Resource
(CARe) [55], and the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) Consortium [56].
Conclusions
In conclusion, UCLEB provides a stable, long-term resource for
large-scale, integrated genomics analyses, with the potential to add
proteomic and metabolomic technologies as they emerge. The
archived biological samples will facilitate more comprehensive
phenomic analysis to match the breadth of genomic data. The
integration of multiple layers of –omics data within the framework
of cohort studies should eventually lead to a more comprehensive
understanding of the mechanisms of common disease [57]. We
recognise that very large sample sizes are required for assessments
of gene-environment interactions (more so for disease outcomes
than quantitative traits) and are likely to require ‘‘consortia of
consortia’’. Therefore, UCLEB will also continue to collaborate
externally and contribute to the wider research efforts focused
around specific diseases and phenotypes. UCLEB will do this by
building on an already extensive network of successful links with
other investigators in the UK and internationally, that will permit
powerful large-scale analyses.
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